IMAPAC Biologics World Korea 2025

Biologics Manufacturing Korea 2025 Songdo Convensia, Incheon, South Korea (September 25–26, 2025)

Biologics Manufacturing Korea 2025 returns for its 14th edition as the premier platform dedicated to advancing South Korea’s biologics and biomanufacturing sector. The event begins on September 24 with two exclusive pre-conference activities: a site tour of Prestige Biologics, offering an insider’s look at a cutting-edge manufacturing facility, and a pre-conference workshop led by a world-leading manufacturing automation solutions partner, designed to provide actionable insights into the future of smart bioproduction. These sessions set the stage for two days of rich discussion and collaboration.

The main conference agenda spans a comprehensive range of topics including upstream and downstream processing, biosimilars development, bioprocess automation, analytics and quality, and supply chain optimization. A strong emphasis will be placed on the integration of predictive analytics and smart facility design to enhance efficiency, scalability, and regulatory compliance. Case studies from the FDA will offer valuable perspectives on process validation and quality control, while sessions on single-use technologies and advanced membrane filtration will showcase innovations in purification and yield improvement.

The event is expected to bring together key decision-makers and innovators shaping the future of biologics manufacturing in the region. Participating organizations include Samsung Biologics, Lotte Biologics, SK bioscience, GC Biopharma, Medytox, and solution providers such as MasterControl, alongside academic institutions like the International Vaccine Institute and Yonsei University. With forward-looking content and unparalleled networking opportunities, the 14th Biologics Manufacturing Korea 2025 conference serves as a central hub for industry professionals driving excellence in biologics production.

ADC & Bioconjugate East Asia 2025 Songdo Convensia, Incheon, South Korea (September 26, 2025)

ADC & Bioconjugate East Asia 2025 will focus on the evolving landscape of ADCs in oncology and beyond. Held on September 26, the conference features a Leadership Panel Discussion on current market trends and future directions for ADCs, exploring applications beyond oncology, such as autoimmune and infectious diseases, investment trends, and regulatory pathways.

Through the conference, attendees can expect expert-led, highly interactive discussions focused on the South Korea, Japan, China, and Taiwan markets. Park Tae Kyo, Chief Executive Officer, Intocell, will present a session on advancing payloads and linker technologies for next-generation ADCs. In the same session, Doo Young Jung, CEO, PinotBio, will shed a new perspective on the development of novel dual payload ADCs, highlighting the Pinot-AD2C platform. Bryan Yeung, Vice President of Chemistry, Axcynsis Therapeutics, will introduce the preclinical development of AT2604, targeting ALPP/ALPPL2. Finally, in another notable session, Xueming Qian, CEO, Transcenta Holding, and Robert Chen, Director ADC, Innolake Biopharma, will discuss optimizing ADC target selection and engineering for maximum efficacy.

The conference delves into scaling up ADC production, advancements in bioconjugation technologies, and innovations in payloads and linker technologies, providing attendees with a comprehensive understanding of the latest developments in ADCs and bioconjugates.

Cell & Gene Therapy East Asia 2025 Songdo Convensia, Incheon, South Korea (September 25, 2025)

Cell & Gene Therapy East Asia 2025 convenes experts from South Korea, Japan, China, and Taiwan to discuss breakthroughs in regenerative medicine over a full-day conference on September 25. The agenda features a Leadership Panel Discussion on the strategic overview of cell and gene therapy (CGT) in East Asia, with insights from Manh-Cuong Vo, General Manager, R&D Center, Vaxcell-Bio. Sessions cover scaling manufacturing processes, with KwangJun Yoon, CHA Biotech, discussing advancements in scalable CGT manufacturing. Lee Heon Ju, CEO, CarBio Therapeutics, presents the development of 5th-generation CAR-T cells targeting late-stage metastatic cancers. Seokjoong Kim, Chief Strategy Officer, GenEdit, explores innovations in polymer-based delivery systems for genomic medicine.

The conference also addresses regulatory landscapes across East Asia, CAR-T and CAR-NK therapies, and gene editing applications, providing a comprehensive view of the region’s CGT advancements. Attendees gain valuable insights into the challenges and opportunities shaping the future of precision medicine in East Asia.

From biomanufacturing leaders to cell therapy pioneers, IMAPAC’s Biologics World Korea 2025 is your gateway to cutting-edge biologics production, next-generation cell and gene therapies, and novel ADC innovations. Uniting three powerhouse conferences, this event equips you with the insights, tech, and partnerships to accelerate pipelines, scale manufacturing, and lead Asia’s biopharma revolution.

As a reader of Bioconjugation Insights, you are entitled to a 15% discount on delegate tickets for the events! Just contact the team at biologicsworld@imapac.com specifying the event you are interested in attending and that you are a reader of the journal. You can find out more about the Biologics World Korea 2025 events here.

Additionally, to find out what other bioconjugate events are upcoming, you can find our online Events Calendar here.